Fereshteh Valizadeh

Fereshteh Valizadeh

Auto-generated profile, based on publicly available information

Fereshteh Valizadeh

Faculty of Medicine Shahid Beheshti University of Medical Sciences (SBUMS) Tehran Iran

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 July 2025 in Food Science & Nutrition
Verified
Journal Article
Open access
MKMehdi Karimi
Mehdi Karimi
MJMeysam Javadi
Meysam Javadi
MSMaryam Sharifi
Maryam Sharifi
FVFereshteh Valizadeh
Fereshteh Valizadeh
MKMohammad Amin Karimi
Mohammad Amin Karimi
OAOmid Asbaghi
Omid Asbaghi
Chronic diseases and inflammation are often linked to elevated liver enzymes and inflammatory markers. Studies suggest that curcuminoid and piperine co‐supplementation (Cur + Pip), which enhances bioavailability, may offer beneficial effects. However, previous findings have been inconsistent. This meta‐analysis aims to evaluate the effectiveness of Cur + Pip on liver enzymes and inflammation in adults. A comprehensive search of scientific databases was conducted until April 2025 to identify relevant randomized controlled trials (RCTs) involving adults. Included studies compared Cur + Pip with placebo, control, or no treatment, focusing on changes in liver enzymes and inflammatory markers as main outcomes. Data from eligible studies were extracted, and pooled effect sizes were calculated using weighted mean differences (WMDs) with 95% confidence intervals (CIs) under a random‐effects model. The pooled analysis of 18 RCTs showed that Cur + Pip significantly reduced AST (WMD: −2.29 IU, p = 0.019) and IL‐6 (WMD: −5.59, p < 0.001), whereas changes in ALT (WMD: −3.88 IU, p = 0.053), ALP (WMD: −15.74 IU, p = 0.095), CRP (WMD: −1.53 mg/dL, p = 0.222), and TNF‐α (WMD: −0.77, p = 0.314) were not statistically significant. Subgroup analysis revealed that reductions in ALT were significant in individuals with metabolic dysfunction (WMD: −4.64 IU, p = 0.044) and adults with overweight (WMD: −4.89 IU, p = 0.048). AST reductions were more pronounced in prolonged supplementation (≥ 12 weeks) (WMD: −4.08 IU, p < 0.001) and in overweight participants (WMD: −3.04 IU, p = 0.020). Cur + Pip demonstrated beneficial effects on liver enzymes, particularly AST, and showed a positive trend for ALT, especially in overweight or metabolically at‐risk individuals. The observed reduction in IL‐6 supports their potential anti‐inflammatory properties, although no significant effects were seen for CRP or TNF‐α. These findings suggest therapeutic promise in specific populations, but further large‐scale, long‐duration trials are necessary to confirm efficacy and establish clinical significance.

16 May 2026 in Nutrition and Cancer
Verified
Journal Article
Closed access
MKMehdi Karimi
Mehdi Karimi
RRReyhaneh Rabiee
Reyhaneh Rabiee
NANahal Babaeian Amini
Nahal Babaeian Amini
FVFereshteh Valizadeh
Fereshteh Valizadeh
MAMina Ahmadzadeh
Mina Ahmadzadeh
BLBagher Larijani
Bagher Larijani
Breast cancer represents a major global public health challenge and is the most frequently diagnosed malignancy among women worldwide, as well as a leading cause of cancer-related mortality (1). It...

7 October 2026 in Food Science & Nutrition
Verified
Journal Article
Open access
MKMehdi Karimi
Mehdi Karimi
KKKimia Kazemi
Kimia Kazemi
FZFatemeh Ziyafati
Fatemeh Ziyafati
FVFereshteh Valizadeh
Fereshteh Valizadeh
NSNiyousha Shirsalimi
Niyousha Shirsalimi
OAOmid Asbaghi
Omid Asbaghi
Dyslipidemia is a major risk factor for cardiovascular disease. Studies have shown that vitamin E has therapeutic effects on lipid metabolism; however, findings remain inconsistent. This meta‐analysis aims to assess the effectiveness of vitamin E administration on the serum lipid panel in patients with dyslipidemia. A database search through January 2026 was conducted to identify relevant randomized controlled trials (RCTs). Relevant data, including triglycerides (TG), total cholesterol (TC), and low‐ and high‐density lipoprotein cholesterol (LDL‐C and HDL‐C), were extracted. The overall effect size was estimated using weighted mean differences (WMDs) with 95% confidence intervals (CIs) via a random‐effects model. The pooled analysis of 22 RCTs (33 intervention arms) demonstrated that vitamin E significantly lowered TG (WMD: −8.14 mg/dL, p = 0.021) and raised HDL‐C (WMD: 1.08 mg/dL, p = 0.037) in patients with dyslipidemia, whereas reductions in TC (WMD: −6.48 mg/dL, p = 0.097) and LDL‐C (WMD: −9.06 mg/dL, p = 0.063) were not significant overall. Exploratory subgroup analyses suggested that tocotrienols may exert greater lipid‐modifying effects than tocopherols, with potentially larger benefits observed at lower doses, among individuals with more pronounced baseline lipid abnormalities, and during shorter intervention periods. In conclusion, vitamin E supplementation in patients with dyslipidemia shows modest improvements in lipid profiles, mainly lowering TG and increasing HDL‐C, with less consistent effects on TC and LDL‐C. Tocotrienols may be more effective than tocopherols, suggesting possible isoform‐specific effects, but overall clinical impact appears limited and requires further confirmation.

26 July 2026 in Endocrinology, Diabetes & Metabolism
Verified
Journal Article
Open access
PDF file
MKMehdi Karimi
Mehdi Karimi
ATAli Tahmasebi
Ali Tahmasebi
SRSepehr Ramezanipour
Sepehr Ramezanipour
FRFatemeh Naseri Rad
Fatemeh Naseri Rad
FVFereshteh Valizadeh
Fereshteh Valizadeh
MPManijeh Ebrahimzadeh Pirshahid
Manijeh Ebrahimzadeh Pirshahid
Background: Metabolic dysfunction‐associated steatotic liver disease (MASLD) is increasingly prevalent and associated with obesity and dyslipidemia, yet effective pharmacological interventions remain limited. Empagliflozin has shown potential benefits in MASLD, although evidence remains limited. This systematic review and meta‐analysis assesses the efficacy of empagliflozin in patients with MASLD, both diabetic and non‐diabetic. Methods: An advanced database search was conducted up to June 1st, 2026, to identify eligible randomized controlled trials (RCTs). The relevant data were extracted from selected studies. Pooled effect sizes were calculated as weighted mean differences (WMDs) with 95% confidence intervals (CIs) using a random‐effects model. Results: Seven RCTs comprising 591 participants were included. Empagliflozin significantly improved liver enzyme profiles. Specifically, it reduced alanine aminotransferase (ALT) (WMD: −12.24 IU/L; p = 0.037), aspartate aminotransferase (AST) (WMD: −9.51 IU/L; p = 0.048), and gamma‐glutamyl transferase (GGT) (WMD: −14.92 IU/L; p = 0.023). Reductions in alkaline phosphatase (ALP) were observed but did not reach statistical significance (WMD: −26.28 IU/L; p = 0.292). Although substantial heterogeneity was observed for several liver enzyme outcomes. Empagliflozin had no significant effect on lipid parameters, including triglycerides (TG), total cholesterol (TC), low‐density and high‐density lipoprotein cholesterols (LDL‐C, HDL‐C). Empagliflozin also produced a statistically significant but modest reduction in body mass index (BMI) (WMD: −0.71 kg/m 2 ; p < 0.001). Empagliflozin also produced a statistically significant but clinically modest reduction in BMI (WMD: −0.71 kg/m 2 ; 95% CI: −1.00 to −0.43; p < 0.001). Conclusion: Empagliflozin appears to improve liver enzymes and modestly reduce BMI in patients with MASLD, while having a neutral effect on lipid parameters. These findings may confer a statistically significant but clinically modest benefit, particularly in patients with coexisting metabolic risk factors. However, the evidence is limited by small sample sizes, short follow‐up periods, and potential publication bias; therefore, the conclusions should be considered preliminary and hypothesis‐generating.